Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer

BACKGROUND: Castration-resistant prostate cancer (CRPC) with sustained androgen receptor (AR) signaling remains a critical clinical challenge, despite androgen depletion therapy. The Jumonji C-containing histone lysine demethylase family 4 (KDM4) members, KDM4A‒KDM4C, serve as critical coactivators...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jai-Shin, Fang, Wei-Kai, Yang, Shan-Min, Wu, Meng-Chen, Chen, Tsan-Jan, Chen, Chih-Ming, Lin, Tung-Yueh, Liu, Kai-Lun, Wu, Chien-Ming, Chen, Yun-Ching, Chuu, Chih-Pin, Wang, Ling-Yu, Hsieh, Hsing-Pang, Kung, Hsing-Jien, Wang, Wen-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082844/
https://www.ncbi.nlm.nih.gov/pubmed/35534851
http://dx.doi.org/10.1186/s12929-022-00812-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082844/
https://www.ncbi.nlm.nih.gov/pubmed/35534851
http://dx.doi.org/10.1186/s12929-022-00812-3

Ejemplares similares